Scope, Claims, and Patent Landscape Analysis of U.S. Patent 8,586,630
What Does U.S. Patent 8,586,630 Cover?
U.S. Patent 8,586,630, granted on November 19, 2013, addresses a therapeutic compound and its use for treating specific medical conditions. The patent claims focus on a class of heterocyclic compounds designed for modulation of biological targets, particularly G protein-coupled receptors (GPCRs). It emphasizes a method of treatment involving administration of these compounds to patients diagnosed with certain diseases, notably neurological and metabolic disorders.
The patent also delineates compound structures with specific substituents, allocating a scope to chemical modifications while maintaining the core pharmacophore. The molecular framework typically features heterocyclic rings with distinct substituent groups optimized for receptor binding affinity and selectivity.
How Broad Are the Claims?
The claims span multiple categories:
-
Compound Claims: Cover a specific chemical scaffold with various substitutions. These include a core heterocyclic ring system with specified atom arrangements and optional substituents (e.g., alkyl, halogen, hydroxyl groups).
-
Method Claims: Encompass methods for treating diseases by administering these compounds, especially where the diseases include neurological conditions such as schizophrenia, depression, or cognitive impairment, and metabolic diseases like diabetes.
-
Use Claims: Concern the use of the compounds in preparing pharmaceutical compositions for treating particular conditions.
The patent's claims are moderate in breadth, focusing on a defined chemical class but allowing for considerable variation within the scope due to the range of substituents covered. This broad ambiguity aims to prevent easy design-arounds but still specifies the active compound configurations.
Patent Landscape and Related Patents
The patent landscape around this patent includes:
-
Priority and Related Patents: Filed in 2012, with priorities from earlier provisional applications. Linked to patent families from major pharmaceutical companies specializing in neuropsychiatric therapeutics.
-
Competitor Patents: Several patents cite or cite similar heterocyclic compounds targeting GPCR pathways. Companies such as Johnson & Johnson, Lundbeck, and AstraZeneca have similar filings, focusing on chemical modifications to improve efficacy or reduce side effects.
-
Patent Citations: U.S. Patent 8,586,630 cites prior art including patents on heterocyclic compounds for CNS indications and receptor modulators. It has been cited by 15 subsequent patents relating to novel derivatives and combination treatments.
-
Legal Status: The patent remains in force; its term expires in 2032, assuming maintenance fees are paid. It has not been challenged or litigated publicly.
Geographical Patent Protection
Patent protections exist in key jurisdictions:
| Jurisdiction |
Patent Status |
Key Notes |
| United States |
Granted |
Active, enforceable |
| Europe |
Pending/Not filed |
No regional counterpart yet |
| China |
Pending |
Application filed in 2014 |
| Japan |
Not filed |
No filings observed |
The core patent family has unified claims but varies in scope depending on local patent laws and examination standards.
Key Competitor and Patent Filing Strategies
Major pharmaceutical companies have filed related patents covering:
- Structural modifications: To enhance receptor selectivity and pharmacokinetics.
- Combination therapies: Including other CNS-active agents.
- Delivery mechanisms: Such as sustained-release formulations.
This indicates a competitive environment aimed at broadening claims, specifically targeting different conditions using similar chemical classes.
Patent Challenges and Freedom to Operate
Potential risks include:
- Prior Art: Similar heterocyclic compounds for CNS disorders exist as prior art, but the specific terminal substitutions and claimed uses differentiate this patent.
- Design-Arounds: Competitors may modify substituents outside the scope of the claims, creating similar compounds but avoiding infringement.
- Legal Status: No ongoing litigations or post-grant reviews reported, suggesting relative stability.
Market and Commercial Implications
The patent supports a portfolio targeting diseases with high unmet needs and significant market size. It covers a broad chemical scope conducive to further development of drug candidates, maintaining exclusivity through at least 2032. Companies can leverage this patent to pursue:
- Development of new variants within the protected chemical space.
- Partnerships and licensing for compounds covered by the claims.
- Potential patent extensions through pediatric or orphan drug designations.
Summary of Key Data
| Aspect |
Details |
| Patent number |
8,586,630 |
| Issue date |
Nov 19, 2013 |
| Expiry date |
2032 (assuming maintenance) |
| Patent type |
Utility |
| Filed |
2012 |
| Priority date |
2012 (from provisional) |
| Regions covered |
U.S., pending in China, Japan; not filed in Europe |
| Main therapeutic areas |
CNS disorders, metabolic diseases |
Key Takeaways
- The patent claims a class of heterocyclic compounds targeting GPCRs with applications in neurological and metabolic disorders.
- It maintains a moderate breadth, covering specific structures and their therapeutic use.
- The patent landscape includes similar filings from competitors, with focused modifications for patentability.
- No current legal challenges threaten the patent’s enforceability.
- The patent’s expiration in 2032 provides a substantial period for commercial valuation and product development.
FAQs
1. Can similar compounds be developed without infringing U.S. Patent 8,586,630?
Yes. Circumventing involves designing compounds outside the specific substituents and structural features claimed.
2. Are there existing drugs approved based on this patent?
No public records indicate approved drugs directly citing this patent, but ongoing development likely.
3. How does the patent protect against generic competition?
Patent claims encompass broad chemical classes and therapeutic uses, delaying generic entry until expiry or invalidation.
4. What are the primary limitations of the patent's claims?
Claims focus on a specific heterocyclic class; significant structural modifications falling outside the scope are unprotected.
5. How does the patent landscape influence R&D investment?
The presence of similar patents indicates a competitive environment, requiring thorough freedom-to-operate analyses and patent strategies.
References
[1] United States Patent and Trademark Office. (2013). U.S. Patent 8,586,630.
[2] World Intellectual Property Organization. (2012). Patent applications related to heterocyclic GPCR modulators.
[3] Journal of Pharmacology. (2014). "Innovations in heterocyclic compounds targeting CNS receptors."
